SCHEMBL2250240

SCHEMBL2250240

OCc1nc(CN2CCOCC2)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
CXCR4 P61073 1/20 0.50
ALOX15 P16050 2/20 0.44
CYP2C9 P11712 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HRH3 Q9Y5N1 2/20 0.43
HTT P42858 1/20 0.41
ENPP2 Q13822 1/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
DRD2 P14416 2/20 0.40
DRD4 P21917 2/20 0.40
DRD3 P35462 2/20 0.40
CNR1 P21554 1/20 0.39
KCNH2 Q12809 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
EPHA2 P29317 1/20 0.39
KDR P35968 1/20 0.39
EPHB4 P54760 1/20 0.39
KDM4E B2RXH2 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10426668 0.88 SMN1; SMN2 (0.55) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL1935980 0.85 SMN1; SMN2 (0.44) SMN1; SMN2HSD17B10HRH3ENPP2NPC1
SCHEMBL24160695 0.84 SMN1; SMN2 (0.63) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL24160336 0.81 SMN1; SMN2 (0.58) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL20605747 0.79 SMN1; SMN2 (0.69) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL13551047 0.79 SMN1; SMN2 (0.69) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL10884745 0.78 SMN1; SMN2 (0.55) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL307293 0.78 SMN1; SMN2 (1.00) SMN1; SMN2CXCR4ALOX15HSD17B10HRH3
SCHEMBL1419909 0.78 SMN1; SMN2 (0.67) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10
SCHEMBL12654050 0.78 SMN1; SMN2 (0.67) SMN1; SMN2CXCR4ALOX15CYP2C9HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4289838-A2 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2023-12-13 EP disclosed
EP-3599236-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2023-08-23 EP disclosed
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2022-12-29 US disclosed
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2022-08-16 US disclosed
US-20220143002-A1 SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2022-05-12 US disclosed
EP-3932922-A1 SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF ShanghaiTech University (CN) 2022-01-05 EP disclosed
US-20200231567-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2020-07-23 US disclosed
US-10669257-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2020-06-02 US disclosed
EP-3599236-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2020-01-29 EP disclosed
EP-3202460-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2019-06-12 EP disclosed
EP-2536706-B1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORP (US) 2017-06-14 EP disclosed
EP-3106460-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2016-12-21 EP disclosed
US-20160159768-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2016-06-09 US disclosed
US-20160159772-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION 2016-06-09 US disclosed
US-9309219-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2016-04-12 US disclosed
US-20130324518-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2013-12-05 US disclosed
US-8518972-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CELGENE CORPORATION (US) 2013-08-27 US disclosed
EP-2536706-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME Celgene Corporation (US) 2012-12-26 EP disclosed
WO-2011100380-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CELGENE CORPORATION (US) 2011-08-18 WO disclosed
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CELGENE CORPORATION 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130324518-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-20160159768-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-20110196150-A1 Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-10669257-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-20220411402-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-20200231567-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-11414399-B2 Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885
US-20220143002-A1 SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF GLS, SQOR, GCDH SMN1; SMN2 945/4885CXCR4 2739/4885ALOX15 1684/4885
US-20160159772-A1 ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME CYP3A7, CYP3A4, CYP3A43 SMN1; SMN2 3696/4885CXCR4 2121/4885ALOX15 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.